Evidence map›Paper›PMID 21191047›Full record

ArticleJournal of clinical microbiology2011

Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay.

Soumitesh Chakravorty, Bola Aladegbami, Kimberley Thoms, Jong Seok Lee, Eun Gae Lee, Vignesh Rajan, Eun-Jin Cho, Hyunchul Kim, Hyunkyung Kwak, Natalia Kurepina and 5 more

Abstract readValidation Study
In one paragraph

Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Identification and quantification ofJournal of clinical microbiology · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Comparison of the characteristics of Mycobacterium tuberculosis isolates from sputum and lung lesions in chronic tuberculosis patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Soumitesh ChakravortyDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Newark, NJ 07103, USA.
Bola Aladegbami
Kimberley Thoms
Jong Seok Lee
Eun Gae Lee
Vignesh Rajan
Eun-Jin Cho
Hyunchul Kim
Hyunkyung Kwak
Natalia Kurepina
Sang-Nae Cho
Barry Kreiswirth
Laura E Via
Clifton E Barry
David Alland

Funding

Development of a second generation MDR-XDR TB assayU01AI082174 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ALLAND, DAVID · 2009 to 2013
$7.2M
International Research in Korea: Clinical Studies of Drug-Resistant TuberculosisZIAAI001067 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2017
$6.9M
Rapid Diagnosis of XDR TuberculosisR01AI080653 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ALLAND, DAVID · 2009 to 2013
$2.8M
Biomarkers for Esophageal Cancer Progression and PrognosisR01CA130853 · NCI · UNIVERSITY OF ROCHESTER · PI GODFREY, TONY E · 2008 to 2012
$1.8M
Intramural NIH HHSNCI NIH HHS R01 CA130853NIAID NIH HHS AI080653NIAID NIH HHS AI082174NIAID NIH HHS R01 AI080653NIAID NIH HHS U01 AI082174
6 · The paper itself

Abstract

Fluoroquinolones (FQ) are important second-line drugs to treat tuberculosis; however, FQ resistance is an emerging problem. Resistance has been mainly attributed to mutations in a 21-bp region of the Mycobacterium tuberculosis gyrA gene, often called the quinolone resistance-determining region (QRDR). We have developed a simple, rapid, and specific assay to detect FQ resistance-determining QRDR mutations. The assay amplifies the M. tuberculosis gyrA QRDR in an asymmetrical PCR followed by probing with two sloppy molecular beacons (SMBs) spanning the entire QRDR. Mutations are detected by melting temperature (T(m)) shifts that occur when the SMBs bind to mismatched sequences. By testing DNA targets corresponding to all known QRDR mutations, we found that one or both of the SMBs produced a T(m) shift of at least 3.6°C for each mutation, making mutation detection very robust. The assay was also able to identify mixtures of wild-type and mutant DNA, with QRDR mutants identified in samples containing as little as 5 to 10% mutant DNA. The assay was blindly validated for its ability to identify the QRDR mutations on DNA extracted from clinical M. tuberculosis strains. Fifty QRDR wild-type samples, 34 QRDR mutant samples, and 8 heteroresistant samples containing mixtures of wild-type and mutant DNA were analyzed. The results showed 100% concordance to conventional DNA sequencing, including a complete identification of all of the mixtures. This SMB T(m) shift assay will be a valuable molecular tool to rapidly detect FQ resistance and to detect the emergence of FQ heteroresistance in clinical samples from tuberculosis patients.

Indexed as

Anti-Bacterial AgentsBacteriological TechniquesDNA, BacterialDNA GyraseDNA PrimersFluoroquinolonesHumansMycobacterium tuberculosisOligonucleotide ProbesPolymerase Chain ReactionTransition TemperatureTuberculosis, Multidrug-ResistantAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA PrimersFluoroquinolonesOligonucleotide Probes

Identifiers

PMID21191047
PMCPMC3067712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.